BACKGROUND: The thyrotropin (TSH) level or duration of thyroid hormone withdrawal (THW) required to detect stimulated thyroglobulin (Tg) in differentiated thyroid cancer (DTC) monitoring is unknown. The objective of this study was to evaluate the TSH cutoff of >30 μU/mL as a means to detect stimulated Tg ≥2 ng/mL after THW (THW-Tg≥2), and sensitivity of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire for detecting hypothyroid symptoms. METHODS: This was a prospective longitudinal cohort study done at a tertiary academic medical center. Forty-seven patients with DTC undergoing their first Tg stimulation or after previously abnormal Tg stimulation had weekly measurements of TSH and Tg during the 4 weeks THW, and repeated questionnaire assessments. RESULTS:TSH did not reach a plateau in any patient, and in those whose Tg did not remain undetectable, Tg continued to rise. Seventy-five percent of patients had an undetectable Tg <0.2 ng/mL at baseline (95% were <0.5 mg/mL) with 16% remaining undetectable throughout THW. The majority of patients (72.7% and 97.8%) achieved TSH >30 μU/mL by 3 and 4 weeks THW, respectively. Of the 15 patients with maximum stimulated THW-Tg≥2, 38% were detected before the minimal TSH >30 μU/mL cutoff. At 2 weeks THW, 3 had a TSH>30 μU/mL, and none of them had Tg ≥2 ng/mL. At 3 weeks THW, 11 had a TSH >30 μU/mL, and 64% of them had Tg ≥2 ng/mL. Only 60% were detected at 3-week THW regardless of their TSH level. Eighty-six percent were detected by TSH 60-<80 μU/mL. Conversely, all patients whose serum Tg was <0.2 ng/mL when their serum TSH was >20 μU/mL did not achieve a THW-Tg≥2. CONCLUSION: The minimal TSH cutoff of >30 μU/mL was inadequate to detect many patients with final stimulated THW-Tg≥2 during complete THW. TSH >80-100 μU/mL was a better cutoff, achieved in only 53% after 4-week THW. Conversely, we propose a preliminary THW-stopping rule for ending THW early in selected patients. In patients with a Tg <0.2 ng/mL when TSH >20 μU/mL, all had a final stimulated Tg ≤2 ng/mL, potentially saving qualifying patients 40% of THW duration compared to 4-week THW. FACIT-F correlated with TSH, but was not sensitive to detect mild hypothyroidism.
RCT Entities:
BACKGROUND: The thyrotropin (TSH) level or duration of thyroid hormone withdrawal (THW) required to detect stimulated thyroglobulin (Tg) in differentiated thyroid cancer (DTC) monitoring is unknown. The objective of this study was to evaluate the TSH cutoff of >30 μU/mL as a means to detect stimulated Tg ≥2 ng/mL after THW (THW-Tg≥2), and sensitivity of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire for detecting hypothyroid symptoms. METHODS: This was a prospective longitudinal cohort study done at a tertiary academic medical center. Forty-seven patients with DTC undergoing their first Tg stimulation or after previously abnormal Tg stimulation had weekly measurements of TSH and Tg during the 4 weeks THW, and repeated questionnaire assessments. RESULTS:TSH did not reach a plateau in any patient, and in those whose Tg did not remain undetectable, Tg continued to rise. Seventy-five percent of patients had an undetectable Tg <0.2 ng/mL at baseline (95% were <0.5 mg/mL) with 16% remaining undetectable throughout THW. The majority of patients (72.7% and 97.8%) achieved TSH >30 μU/mL by 3 and 4 weeks THW, respectively. Of the 15 patients with maximum stimulated THW-Tg≥2, 38% were detected before the minimal TSH >30 μU/mL cutoff. At 2 weeks THW, 3 had a TSH>30 μU/mL, and none of them had Tg ≥2 ng/mL. At 3 weeks THW, 11 had a TSH >30 μU/mL, and 64% of them had Tg ≥2 ng/mL. Only 60% were detected at 3-week THW regardless of their TSH level. Eighty-six percent were detected by TSH 60-<80 μU/mL. Conversely, all patients whose serum Tg was <0.2 ng/mL when their serum TSH was >20 μU/mL did not achieve a THW-Tg≥2. CONCLUSION: The minimal TSH cutoff of >30 μU/mL was inadequate to detect many patients with final stimulated THW-Tg≥2 during complete THW. TSH >80-100 μU/mL was a better cutoff, achieved in only 53% after 4-week THW. Conversely, we propose a preliminary THW-stopping rule for ending THW early in selected patients. In patients with a Tg <0.2 ng/mL when TSH >20 μU/mL, all had a final stimulated Tg ≤2 ng/mL, potentially saving qualifying patients 40% of THW duration compared to 4-week THW. FACIT-F correlated with TSH, but was not sensitive to detect mild hypothyroidism.
Authors: F Pacini; E Molinaro; F Lippi; M G Castagna; L Agate; C Ceccarelli; D Taddei; R Elisei; M Capezzone; A Pinchera Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: B R Haugen; F Pacini; C Reiners; M Schlumberger; P W Ladenson; S I Sherman; D S Cooper; K E Graham; L E Braverman; M C Skarulis; T F Davies; L J DeGroot; E L Mazzaferri; G H Daniels; D S Ross; M Luster; M H Samuels; D V Becker; H R Maxon; R R Cavalieri; C A Spencer; K McEllin; B D Weintraub; E C Ridgway Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: Reyna Sánchez; Ana Laura Espinosa-de-los-Monteros; Victoria Mendoza; Eduardo Brea; Irma Hernández; Ernesto Sosa; Moisés Mercado Journal: Arch Med Res Date: 2002 Sep-Oct Impact factor: 2.235
Authors: M Brassard; I Borget; A Edet-Sanson; A-L Giraudet; O Mundler; M Toubeau; F Bonichon; F Borson-Chazot; L Leenhardt; C Schvartz; C Dejax; I Brenot-Rossi; M-E Toubert; M Torlontano; E Benhamou; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2011-03-09 Impact factor: 5.958
Authors: F Pacini; E Molinaro; M G Castagna; L Agate; R Elisei; C Ceccarelli; F Lippi; D Taddei; L Grasso; A Pinchera Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: David Taïeb; Karine Baumstarck-Barrau; Frédéric Sebag; Cécile Fortanier; Catherine De Micco; Anderson Loundou; Pascal Auquier; Fausto F Palazzo; Jean-françois Henry; Olivier Mundler Journal: Health Qual Life Outcomes Date: 2011-05-13 Impact factor: 3.186
Authors: A Flores-Rebollar; I Pérez-Díaz; S Lagunas-Bárcenas; B García-Martínez; R Rivera-Moscoso; R Fagundo-Sierra Journal: Acta Otorhinolaryngol Ital Date: 2018-06 Impact factor: 2.124
Authors: Agnese Barnabei; Lidia Strigari; Agnese Persichetti; Roberto Baldelli; Laura Rizza; Claudia Annoscia; Rosa Lauretta; Giovanni Cigliana; Maddalena Barba; Aurora De Leo; Marialuisa Appetecchia; Francesco Torino Journal: Front Endocrinol (Lausanne) Date: 2018-02-15 Impact factor: 5.555